EU Fast Track Sought For Epidermolysis Bullosa Gene Therapy & Bispecific RRMM Drug
Executive Summary
Janssen and Krystal Biotech will soon learn whether the European Medicines Agency considers their respective products to be of potential major public health interest, particularly from the point of view of therapeutic innovation.